Beijing Tong Ren Tang Chinese Medicine Company Limited Issues Important Financial Information Update for Q1 2026

Key Highlights for Investors

• Announcement of Unaudited Financial Information: Beijing Tong Ren Tang Chinese Medicine Company Limited (“the Company”) has issued an announcement regarding the unaudited financial results of its controlling shareholder, Tong Ren Tang Technologies Co. Ltd. (“Tong Ren Tang Technologies”), for the first quarter ended 31 March 2026.
• Publication of Results: Tong Ren Tang Technologies, which is listed on the Main Board of the Hong Kong Stock Exchange (stock code: 1666), has published these unaudited results on the official Stock Exchange website (www.hkexnews.hk).
• Further Financial Disclosure Expected: The ultimate controlling shareholder, Beijing Tong Ren Tang Company Limited (“Tong Ren Tang Ltd.”), will also announce its unaudited Q1 2026 results on or before 30 April 2026 on the Shanghai Stock Exchange (stock code: 600085).

Details Investors Should Note

• Potential Share Price Impact:
  • The release of unaudited financial results by both Tong Ren Tang Technologies and Tong Ren Tang Ltd. provides new insights into the operating performance of the group, which could be price sensitive. Investors should monitor these disclosures closely, as they may influence market perception and share price movement for all related entities, including Beijing Tong Ren Tang Chinese Medicine Company Limited.
  • As the financial information is unaudited and covers only the three months ended 31 March 2026, any significant deviation from market expectations could trigger volatility in the Company’s share price.
• Investor Caution Advised: The Company explicitly advises shareholders and potential investors to exercise caution when dealing in its securities, underlining the potential for price-sensitive information in these quarterly announcements.
• Board Composition: For transparency and governance, the announcement also details the current composition of the Board, including Executive, Non-Executive, and Independent Non-Executive Directors. The leadership is as follows:
  • Executive Directors: Mr. Yan Han (Chairman), Mr. Yue Zheng (Vice Chairman), Mr. Wang Chi
  • Non-executive Director: Ms. Feng Li
  • Independent Non-executive Directors: Mr. Tsang Yok Sing, Jasper; Mr. Xu Hong Xi; Mr. Chan Ngai Chi

Actionable Information for Shareholders

• Shareholders should review the detailed unaudited financial results of Tong Ren Tang Technologies as soon as possible via the Hong Kong Stock Exchange website.
• Investors should also anticipate the upcoming Q1 2026 results of Tong Ren Tang Ltd. on the Shanghai Stock Exchange, as these will provide further context regarding the overall performance and outlook of the group.
• Given the interconnected shareholding structure, financial performance at the parent and controlling shareholder levels may have direct implications for the valuation and perception of Beijing Tong Ren Tang Chinese Medicine Company Limited.

Conclusion

Investors are urged to stay alert for any further announcements and to exercise due diligence when making investment decisions related to the Company, especially in light of the unaudited nature of the reported results and the potential for market-moving information.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are advised to consult the full official announcements and consider their own circumstances before making any investment decisions. Beijing Tong Ren Tang Chinese Medicine Company Limited and its affiliates take no responsibility for any losses arising from reliance on the information provided above.

View TONGRENTANGCM Historical chart here